Progressive Medical Research

Running trials

• Not yet recruiting

  A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)

  NCT07843459· Phase 1· Source

• Recruiting

  A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity

  NCT07843498· Phase 3· Source

• Recruiting

  A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease

  NCT07843472· Phase 3· Source

• Recruiting

  A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

  NCT07787169· Phase 1· Source

• Recruiting

  Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

  NCT07511361· Phase 2· Source

• Recruiting

  A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

  NCT07602582· Phase 3· Source

• Recruiting

  A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

  NCT07633470· Phase 4· Source

• Recruiting

  Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  NCT07575399· Phase 3· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07351058· Phase 3· Source

• Recruiting

  A Study of PATAS Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects

  NCT07223333· Phase 1· Source

• Recruiting

  Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

  NCT07271186· Phase 2· Source

• Recruiting

  A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07288138· Phase 2· Source

• Recruiting

  A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  NCT06937229· Phase 3· Source

• Recruiting

  Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

  NCT07296484· Phase 2· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Source

• Recruiting

  A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

  NCT07787182· Phase 1· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Phase 3· Source

• Recruiting

  A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

  NCT06809400· Phase 1· Source

• Recruiting

  Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

  NCT06847321· Phase 2· Source

• Recruiting

  A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

  NCT06657768· Phase 1· Source

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Source

• Active, not recruiting

  A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

  NCT06602258· Phase 2· Source

• Recruiting

  Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

  NCT06584357· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

  NCT06335173· Phase 2· Source

• Enrolling by invitation

  Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

  NCT06245031· Source

• Active, not recruiting

  Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

  NCT05968430· Phase 3· Source

• Active, not recruiting

  A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

  NCT05738486· Phase 3· Source

• Active, not recruiting

  Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

  NCT05531526· Phase 3· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

  NCT04951219· Phase 3· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Source

• Active, not recruiting

  Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

  NCT04083339· Phase 3· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

  NCT03900429· Phase 3· Source

• Active, not recruiting

  A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

  NCT03887455· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease11 recruiting
• Obesity4 recruiting
• Type 2 diabetes4 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Chronic kidney disease1 recruiting
• High blood pressure1 recruiting
• Parkinson disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)

  NCT07016412· Phase 2· Source

• Completed

  A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)

  NCT06864104· Phase 2· Source

• Completed

  A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

  NCT06675929· Phase 2· Source

• Completed

  A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

  NCT06538116· Phase 2· Source

• Completed

  A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

  NCT06525935· Phase 2· Source

• Terminated

  Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

  NCT06304883· Phase 3· Source

• Completed

  Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

  NCT06005597· Phase 3· Source

• Completed

  Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

  NCT06153693· Phase 3· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

  NCT05929066· Phase 3· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

  NCT05882045· Phase 3· Source

• Completed

  A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

  NCT05769608· Phase 2· Source

• Completed

  Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

  NCT05669599· Phase 2· Source

• Completed

  Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

  NCT05762471· Phase 1/2· Source

• Completed

  A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

  NCT05637801· Source

• Completed

  A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

  NCT05463731· Phase 3· Source

• Completed

  Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

  NCT05142722· Phase 3· Source

• Completed

  Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT04994483· Phase 3· Source

• Completed

  A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

  NCT04880031· Phase 2· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Source

• Completed

  An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

  NCT04770220· Phase 3· Source

• Completed

  A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

  NCT04592874· Phase 2· Source

• Completed

  A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

  NCT04640077· Phase 2· Source

• Completed

  A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

  NCT04451408· Phase 1· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Source